Condition
Mass Spectrometry
Total Trials
6
Recruiting
1
Active
2
Completed
3
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 6 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 3 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
Trial Status
Completed3
Recruiting1
Unknown1
Active Not Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (6)
Showing 6 of 6 trials
NCT06906432Recruiting
Mechanisms of Brain-Heart Injury of Post-Intracranial Hemorrhage
NCT06642506Active Not Recruiting
Oncometabolome and MALDI-MSI in Upper GI Carcinomas - Chemosensitivity in Esophageal Carcinoma
NCT02595632Completed
Breath Analysis in Healthy Controls
NCT02810158Completed
Mass Spectral Fingerprinting in Obstructive Sleep Apnoea
NCT03401957Unknown
The Emergence of RAS Mutations in Metastatic Colorectal Cancer Patients Receiving Cetuximab Treatment
NCT02450461Completed
Breath Analysis in Asthma
Showing all 6 trials